Key result
Amlodipine and indapamide sustained release significantly decreased blood pressure variability after 3 months of treatment (P<0.007 and P<0.04, respectively).
Why the study?
Do different antihypertensive agents (candesartan, indapamide sustained release, amlodipine) reduce blood pressure variability in hypertensive patients?
RCT (n=577)
Double-blind
Yes
Do different antihypertensive agents (candesartan, indapamide sustained release, amlodipine) reduce blood pressure variability in hypertensive patients?
p-value: P<0.007 (amlodipine), P<0.04 (indapamide SR)
Amlodipine and indapamide sustained release significantly reduce blood pressure variability in hypertensive patients, which may offer additional cardiovascular protection beyond absolute BP lowering.
No takes yet. Share an insight, caveat, or question.
Supports amlodipine or indapamide when BP variability reduction is targeted; extends RCT evidence on agent-specific effects beyond mean BP lowering.
Zhang et al. (2011) conducted an RCT in Hypertension (n=577). Candesartan, indapamide sustained release, and amlodipine vs. Placebo was evaluated on Blood pressure variability (BPV) (p=P<0.007 (amlodipine), P<0.04 (indapamide SR)). Amlodipine and indapamide sustained release significantly decreased blood pressure variability after 3 months of treatment (P<0.007 and P<0.04, respectively).